UCSF PROSTATE CANCER SPORE

加州大学旧金山分校前列腺癌孢子

• 批准号: 6661276
• 负责人: MARC A. SHUMAN
• 金额: $ 226.56万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-25 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6661276
• 关键词: neoplasm /cancer genetics; neoplastic process; prostate neoplasms

APPLICANT'S DESCRIPTION The application represents an interdisciplinary approach to improving prevention, diagnosis, and treatment of prostate cancer. UCSF basic scientists and clinical investigators with diverse talents in cell and molecular biology, immunology, genetics, as well as informatics, biostatistics, and conducting phase I studies in prostate cancer are working together to address important problems in this disease. Four projects specifically are designed to improve treatment of advanced prostate cancer using either 1) anti-CTLA4 antibodies 2) mutant adenoviruses and radiation therapy, 3) recombinant human antibodies against prostate cancer antigens, and 4) mutant telomerases. One of the projects will identify new prostate cancer antigens using antibody gene diversity libraries and phage display. In addition, one project is focused on identifying the genetic aberrations in prostate cancer responsible for development and progression of the disease. A related project is focused on identifying modifier genes which determine whether patients develop prostate cancer metastases. Several Cores will provide critical support to the Projects including Cores focused on: Informatics, Clinical Research, Animal Technology; Tissue acquisition and storage, and Administration. In addition, members of a recently formed Prostate Cancer Advocacy Core will work with SPORE investigators to design, and implement optimal approaches to clinical trials.

申请人的描述本申请代表了改进前列腺癌的预防、诊断和治疗的跨学科方法。 加州大学旧金山分校的基础科学家和临床研究人员在细胞和分子生物学、免疫学、遗传学以及信息学、生物统计学方面拥有不同的才能，并开展前列腺癌的一期研究，正在共同努力解决这种疾病的重要问题。 四个项目专门设计用于改善晚期前列腺癌的治疗，使用 1) 抗 CTLA4 抗体 2) 突变腺病毒和放射疗法，3) 抗前列腺癌抗原的重组人抗体，以及 4) 突变端粒酶。 其中一个项目将利用抗体基因多样性文库和噬菌体展示来鉴定新的前列腺癌抗原。 此外，一个项目的重点是确定前列腺癌中导致疾病发生和进展的遗传畸变。 一个相关项目的重点是鉴定决定患者是否发生前列腺癌转移的修饰基因。 多个核心将为这些项目提供关键支持，包括专注于以下领域的核心：信息学、临床研究、动物技术；组织采集和储存以及管理。此外，最近成立的前列腺癌倡导核心成员将与 SPORE 研究人员合作，设计和实施最佳的临床试验方法。